Acurx Announces Positive Phase 2A Clinical Trial Results for Ibezapolstat in C. difficile Infection at Prominent International Conference - PRNewswire
High-throughput screening identifies a novel natural product-inspired scaffold capable of inhibiting Clostridioides difficile in vitro
Clostridioides difficile is an enteric pathogen responsible for causing debilitating diarrhea, mostly in hospitalized patients. The bacterium exploits on microbial dysbiosis induced by the use of antibiotics to establish infection that ranges from mild watery diarrhea to pseudomembranous colitis. Th …
Investigational Clostridioides Difficile Therapy Demonstrates Superiority Over Placebo - Contagionlive.com
Ferring Pharmaceuticals and Rebiotix reported results from a trial on their therapy, RBX2660, which shows promise as a Clostridioides difficile infection (CDI) treatment.
Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection - BioSpace
Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
C. difficile Infection Therapeutic Drug Market to Witness ... C. difficile Infection Therapeutic Drug Market to Witness Growth Acceleration by Top Key Players – Pfizer Inc., Astellas ....
Microbome for c diff works
An investigational microbiome-based therapeutic for C difficile was found to exert continued efficacy 3 months after administration.
Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone Symposium - BioSpace
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that it will present new data from its SER-109 Phase 3 ECOSPOR III clinical study that confirm the intended pharmacological properties of this investigational microbiome therapeutic for recurrent C. difficile infection (CDI).
MGB Biopharma - Successful End-of-Phase 2 Meeting with FDA for MGB-BP-3 a Potential New Gold Standard First-Line Treatment for Clostridioides difficile Infection (CDI) - PRNewswire
/PRNewswire/ -- MGB Biopharma, a biopharmaceutical company developing MGB-BP-3, a novel antibacterial, for the treatment of Clostridioides difficile (CDI),...
The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1 open-label single-group trial - The Lancet
Novel Antibiotic for C diff Enters Phase 2 Clinical Trial - Contagionlive.com
Recruitment for a phase 2 trial of a novel antibiotic against Clostridium difficile (C diff) is proceeding after phase 1 demonstrated safety and tolerability.
In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection
Clostridioides difficile infections (CDIs) are an urgent public health threat worldwide and are a leading cause of morbidity and mortality in healthcare settings. The increasing incidence and severity of infections combined with the scarcity of effective anti-CDI agents has made treatment of CDI ver …
Summit Therapeutics Announces Preclinical Candidate and - GlobeNewswire
Cambridge, MA, May 18, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today that it has selected a new preclinical candidate, SMT026738...
Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW) 2021 - Business Wire